Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Microsure receives CE mark for MUSA-3 system and appoints new CEO
Dutch medical technology company Microsure has secured CE mark approval for its MUSA-3 system and appointed Alex Joseph as its …
-
MEDSIR reports PHERGain and PHERGain-2 trial results for breast cancer
MEDSIR has reported data from the PHERGain and PHERGain-2 trials, which focused on targeted therapies in early human epidermal growth …
-
Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn
Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking …
-
Halozyme and Oruka sign agreement for Hypercon technology
Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics for the development of ORKA-001 using …
-
Patient enrolment concludes in Alebund’s Phase III trial of AP301
Alebund Pharmaceuticals has completed patient enrolment in its global Phase III pivotal clinical trial, RESPOND-2, Study AP301-HP-03, evaluating the fibre-iron-based …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Xtant Medical launches Trivium Shaped allograft for surgeries
US company Xtant Medical Holdings has commercially launched the Trivium Shaped allograft, a new addition to its Trivium bone graft …
-
Medtronic’s VitalFlow Transport Frame AG gains CE mark
Medtronic has received the CE mark for its VitalFlow Transport Frame Air and Ground (AG), which functions as an accessory …
-
Nocion completes patient enrolment in Phase IIb ASPIRE trial
Nocion Therapeutics has completed patient enrolment in its Phase IIb ASPIRE study assessing taplucainium as a treatment for refractory or …
-
MSD concludes Terns acquisition to expand CML pipeline
Merck & Co (MSD) has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia …
-
Tell us: Is hospital connectivity keeping up with the demands of modern care in 2026?
For years, healthcare organizations have focused on enabling clinical mobility by giving clinicians access to systems, communication tools, and patient …
-
Insulet begins patient enrolment for EVOLVE trial
Insulet has commenced patient enrolment in its pivotal EVOLVE study, evaluating a fully closed-loop automated insulin delivery (AID) system for …
-
Takeda’s Phase II/III trial of TAK-881 meets primary endpoint
Takeda’s TAK-881-3001 pivotal Phase II/III clinical trial of TAK-881 in patients with primary immunodeficiency disease (PID) has met its primary …
-
Latus Bio secures $97m in funding to boost gene therapy access
Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies to wider …
-
FDA grants 510(k) clearance to TaeWoong Medical for Spaxus EUS stent
US-based TaeWoong Medical has secured the US Food and Drug Administration (FDA) clearance to commercialise the Niti-S Spaxus Stent, expanding …
-
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
Celcuity has reported topline outcomes from the PIK3CA mutant cohort of the Phase III VIKTORIA-1 clinical trial assessing gedatolisib combined …
